Menu Search
Equities

StemRIM Inc

4599:TYO

StemRIM Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)453.00
  • Today's Change5.00 / 1.12%
  • Shares traded135.40k
  • 1 Year change-38.03%
  • Beta1.8227
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year StemRIM Inc's revenues fell -100.00% from 2.35bn to 0.00. has gone from a gain of 168.35m to a loss of 2.02bn.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-20.44%
Return on equity-20.99%
Return on investment-20.74%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at StemRIM Inc fell by 1.81bn. Cash Flow from Financing totalled 78.97m or -- of revenues. In addition the company used 1.88bn for operations while cash used for investing totalled 4.78m.
Cash flow per share-24.23
Price/Cash flow per share--
Book value per share144.57
Tangible book value per share144.53
More ▼

Balance sheet in JPYView more

StemRIM Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio131.47
Quick ratio131.03
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items dropped -1,324.95%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-4,667.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.